Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC.

Kaweh BeizaeiLisa GleißnerKonstantin HofferLara BußmannAnh Thu VuLeonhard SteinmeisterSimon LabanNikolaus MöckelmannAdrian MünscherCordula PetersenKai RothkammMalte Kriegs

Published in: Head & neck (2018)

We identified MET as a new potential target of sorafenib. However, MET inhibition is not the cause for sorafenib-mediated cytotoxicity or radiosensitization.